Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

http://www.wikidata.org/entity/Q35523144

about

Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 Active immunization in the United States: developments over the past decade.Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice Parameters underlying successful protection with live attenuated mutants in experimental shigellosis Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.Prevention and self-treatment of traveler's diarrhea.Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.Broadly protective Shigella vaccine based on type III secretion apparatus proteins.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Expression of Shigella flexneri ipaB Gene in Tobacco.Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.Progress and pitfalls in Shigella vaccine research.Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.Shigella Vaccine Development: Finding the Path of Least Resistance.Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.

P2860

Q28343287-095455ED-7945-4E33-B8DD-E703E549F96E Q33975799-BCA36C6F-C18C-45DF-A533-9B05D4BDA396 Q34002272-D25631F0-3BEF-4100-B1E4-047A3FFCAAE4 Q34006071-BD1DF3CA-326D-4E8F-B1EB-00B0ECA4FAC9 Q34006223-7E334808-6923-4780-B080-061E0A285373 Q34974972-AB3EBB63-86F7-41AF-956C-2BB938325984 Q35598035-7CC3C7CA-18F2-4773-8AF6-0221272DA0F6 Q35805439-1F58C140-43AE-43A8-8CA9-5B820745D747 Q36844719-EE23FD9F-7656-4020-9462-F914426563A7 Q36946812-8CB0EB7B-09A3-432A-9C70-0117C4FD493E Q37032264-EFB92821-07A1-4C52-BCEA-C7FE54B48A3B Q37105553-A470040F-F5EB-4AB2-A200-43C5CB3433EE Q37163698-948D90B1-30A1-4582-B99D-09784710E90E Q37477191-824E3496-1988-4954-8F2B-84C5D97F59FB Q39519924-21705725-DAC4-4BF5-8D49-85E651F0F365 Q42120657-A642BCA3-2335-4569-8A09-DBB890BDA0B2 Q55310096-6DE82E02-F3CF-48D7-9692-4E5F6735D477

P2860

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

http://www.wikidata.org/entity/Q35523144

description

1996 nî lūn-bûn

@nan

1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@ast

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@en

type

label

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@ast

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@en

prefLabel

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@ast

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@en

P1433

Q35523144-8BA1E68D-C860-4809-A398-117349EA51E5

P1476

Q35523144-F15C6FD5-DC60-4723-8F8F-E1EBFB7A3CC7

P2093

Q35523144-10C1CD8C-D924-4F0C-8BC8-E8FFEEA61924

Q35523144-11C97BEB-0824-4118-8008-63A1B2775696

Q35523144-3B8DBF35-A5CA-426B-B556-DA78C52F8F04

Q35523144-42895AF7-AF13-4124-95E5-A3C5CF91D1B0

Q35523144-4E1AEE40-4EAB-4768-B63D-C82DCD23B2F3

Q35523144-6B6D4174-8E41-48AF-8B47-B018651C4E05

Q35523144-6D334D0E-F9FD-4B5B-B3AF-D4903640B7B9

Q35523144-752D760E-8F54-4BFC-8A24-7E02404EAF66

Q35523144-95DFC65D-7673-4B0F-9996-2FA6F5AA6DE6

Q35523144-A913119B-8607-4C3A-BF31-15224F972A08

P2860

Q35523144-06BCA93E-C4A0-4B5B-A4F5-C60F5AF92776

Q35523144-0D9628ED-7C9F-4A2C-974C-45A0766E7047

Q35523144-1A7D9E10-9FBF-4542-92E6-E92A559919C1

Q35523144-202EF774-8643-4035-ADA9-DC81CC3224E6

Q35523144-20442ACE-C1D7-43B1-9681-D03CBC09B352

Q35523144-247B1446-CE6C-457C-9B61-58AC31CCF63A

Q35523144-37B9F324-90E4-4BDB-A5EA-4DD69033E540

Q35523144-615AD5DE-98BA-49B8-BA2B-5601A594772A

Q35523144-73E62C9B-C255-422B-80F7-88D4B4F7D6E5

Q35523144-7B273D74-5A22-4B76-B98C-D280D2AECB1B

P304

Q35523144-01FBA47A-0A4D-48DF-BC45-76EF60E818F9

P31

Q35523144-157ACEA0-D279-4FB1-A8A9-908A799E4D37

P407

Q35523144-545FAFBF-D20D-433C-9128-969A7C76FB71

P433

Q35523144-FF00B772-CF25-4F0A-AC45-55EFD4EACBFE

P478

Q35523144-7C44A0F9-E633-4484-BCE9-0342CFABA827

P577

Q35523144-C8EA7C48-0D7C-4A8C-8603-4D914262D62F

P698

Q35523144-A4DD383F-E41A-43C2-8AFB-DC50B61FCE6E

P921

Q35523144-068DF1F4-23D6-4900-9512-8CACCC0A687D

P932

Q35523144-0A9CA4D4-BBBB-4436-9D1C-0E219A5DA251

P1433

Infection and Immunity

P1476

Safety and immunogenicity of i ...... accines in Israeli volunteers.

@en

P2093

Ashkenazi S

http://www.w3.org/2001/XMLSchema#string

Chu C

http://www.w3.org/2001/XMLSchema#string

Cohen D

http://www.w3.org/2001/XMLSchema#string

Green M

http://www.w3.org/2001/XMLSchema#string

Lerman Y

http://www.w3.org/2001/XMLSchema#string

Orr N

http://www.w3.org/2001/XMLSchema#string

Robbins JB

http://www.w3.org/2001/XMLSchema#string

Robin G

http://www.w3.org/2001/XMLSchema#string

Sadoff JC

http://www.w3.org/2001/XMLSchema#string

Schneerson R

http://www.w3.org/2001/XMLSchema#string

P2860

Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid

Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides.

Antibody-secreting peripheral blood lymphocytes induced by immunization with a conjugate consisting of Streptococcus pneumoniae type 12F polysaccharide and diphtheria toxoid.

Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei

Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections

Polysaccharide-protein conjugates: a new generation of vaccines.

Four decades of shigellosis in Israel: epidemiology of a growing public health problem.

Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.

P304

4074-4077

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

1996-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8926071

http://www.w3.org/2001/XMLSchema#string

P921

P932

174339

http://www.w3.org/2001/XMLSchema#string